內克塔治療 NKTR 深 滬
已收盤 05-08 16:00:00 美东时间
81.89
-1.480
-1.78%
華盛通- 最 高84.94
- 今 開84.94
- 成交量 72.28万股
- 最 低 80.91
- 昨 收 83.37
- 總市值 27.63亿
- 52周最高 109.00
- 市盈率 靜 --
- 換手率 2.14%
- 52周最低 7.99
- 委 比 -52.14%
- 總股本 3374.21万
- 歷史最高 1670.40
- 量 比 1.07
- 振 幅 4.83%
- 歷史最低 6.189
- 每 手 1
- 風險率 23.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Nektar Therapeutics Charts Aggressive Path With REZPEG
Nektar Therapeutics (($NKTR)) has held its Q1 earnings call. Read on for the ma...
05-09 08:51
Nektar Therapeutics Establishes New Equity Distribution Agreement
Nektar Therapeutics ( ($NKTR) ) has issued an update. On May 8, 2026, Nektar Th...
05-09 06:21
Piper Sandler Maintains Overweight on Nektar Therapeutics, Raises Price Target to $192
Piper Sandler analyst Yasmeen Rahimi maintains Nektar Therapeutics (NASDAQ:NKTR) with a Overweight and raises the price target from $105 to $192.
05-08 23:09
财报速睇 | 内克塔治疗 2026财年Q1营收0.11亿美元，同比增长3.8%；归母净利润亏损0.45亿美元，同比亏损缩窄11.7%
华盛资讯5月8日讯，内克塔治疗公布2026财年Q1业绩，公司Q1营收0.11亿美元，同比增长3.8%，归母净利润亏损0.45亿美元，同比亏损缩窄11.7%。
05-08 07:17
AEVEX Stock Is Surging Thursday: Post-IPO Momentum Explained
AEVEX Corp (NYSE:AVEX) shares are trading higher on Thursday as traders keep leaning into the post-IPO momentum in a high-volatility phase.
04-23 22:48
U.S. RESEARCH ROUNDUP-CME Group, GE Vernova, Texas Instruments
U.S. RESEARCH ROUNDUP-CME Group, GE Vernova, Texas Instruments April 23 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including CME Group, GE Vernova and Texas Instruments on Thursday. HIGHLIGHTS * CME Group Inc CME.O : JP Morga
04-23 15:46
美股大行评级 | 瑞银大幅上调西部数据、希捷科技目标价！汇丰银行上调英特尔评级至"买入"，目标价从50美元升至95美元
今日重点评级关注：HC Wainwright & Co.：维持Century Therapeutics"买入"评级，目标价从2美元升至5美元；Oppenheimer：维持Climb Bio"跑赢大市"评级，目标价从10美元升至18美元
04-22 12:41
美股机会日报 | 沃什今晚“国会山”首秀！“大空头”称科技巨头盈利被高估逾4成；联合健康盘前大涨7%
美联储新主席呼之欲出？沃什今夜十点将出席提名听证会；“大空头”再唱空！伯里称科技巨头盈利被高估逾4成；联合健康盘前大涨7%，公司计划Q2回购20亿美元股份>>
04-21 20:13
美股大行评级 | 大摩上调Lumentum目标价从595美元升至710美元；康宁、道富银行、Ally Financial获多家机构上调目标价
今日重点评级关注：Canaccord Genuity：维持Vertical Aerospace"买入"评级，目标价从9.5美元升至10.5美元；Canaccord Genuity：维持AtaiBeckley Inc."买入"评级，目标价从14美元升至15美元
04-21 11:25
Nektar Therapeutics announces $250M public offering
Nektar Therapeutics (NKTR) announced on Monday that it has commenced an underwritten public offering of $250M of its shares of its common stock and, in lieu of common stock to certain investors, pre-f...
04-21 04:11
